Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Clinical Study to Investigate the Efficacy and Safety of Wilate during Prophylaxis in Previously Treated Patients with Von Willebrand Disease (VWD)

Robert F. Sidonio, Jr., MD MSc, Bruce A. Schwartz, PhD

Blood (2019) 134 (Supplement_1): 4931.

https://doi.org/10.1182/blood-2019-128339

Published: 2019

Journal Articles

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

Johannes Oldenburg, MD PhD, Anna Pavlova, MD PhD, Susan Halimeh, MD, Robert Klamroth, Joris Versteden, Martina Jansen, Larisa Belyanskaya, PhD

Blood (2018) 132 (Supplement 1): 5034.

https://doi.org/10.1182/blood-2018-99-116577

Published: 2018

Journal Articles

A Novel Approach to Immune Tolerance Induction in Hemophilia Α with Factor VIII Inhibitor

Courtney D. Thornburg, MD, Jonathan M. Ducore, MD

Blood (2018) 132 (Supplement 1): 5042.

https://doi.org/10.1182/blood-2018-99-119800

Published: 2018

Journal Articles

Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project

Blood (2018) 132 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2018-99-112447

Published: 2018

Journal Articles

Final Results from a Non-Interventional Safety and Efficacy Study of a VWF/FVIII Concentrate (wilate ® ) in Patients with Von Willebrand Disease

Hassan M. Yaish, MD, Maria Sol Cruz, MD, Kay Decker, Eva M.K. Zetterberg, MD PhD, Sylvia Werner, Mariko Hashimoto, Sigurd Knaub, George M. Rodgers, MD PhD

Blood (2018) 132 (Supplement 1): 1182.

https://doi.org/10.1182/blood-2018-99-118069

Published: 2018

Journal Articles

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Spero R Cataland, MD, Marie Scully, MD MRCP, FRCPath, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Rui Passos Sousa, MD MSc, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 1142.

https://doi.org/10.1182/blood-2018-99-112179

Published: 2018

Journal Articles

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

Ri Liesner, Joris Versteden, Shannely Lowndes, Larisa Belyanskaya, PhD, Johannes Oldenburg, MD PhD, Anna Pavlova, MD PhD

Blood (2018) 132 (Supplement 1): 1204.

https://doi.org/10.1182/blood-2018-99-110608

Published: 2018

Journal Articles

Immune Tolerance Induction in Hemophilia A Patients Using Wilate® —a Canadian 10 Year Study (PREVAIL)

Paul Moorehead, MD, Mark J. Belletrutti, MD MSc, David Lillicrap, MD FRCPC, Robert J Klaassen, MD FRCPC, Manuel Carcao, MDMSc, Georges E. Rivard, MD FRCPC

Blood (2017) 130 (Supplement 1): 3679.

https://doi.org/10.1182/blood.V130.Suppl_1.3679.3679

Published: 2017

Journal Articles

Management of Perioperative Anticoagulation in Patients with VWD

Mario Von Depka, MD PhD, Carsten Detering, MSc, Stefanie Döpke, Mahnaz Ekhlasi-Hundrieser, PhD

Blood (2015) 126 (23): 1100.

https://doi.org/10.1182/blood.V126.23.1100.1100

Published: 2015

Journal Articles

A Case Series Evaluating the Use of a Von Willebrand Factor/Factor VIII Concentrate (Wilate®) for Immune Tolerance Induction (ITI) in Children with Severe Factor VIII Deficiency

Mark J. Belletrutti, MD MSc, Roxanne Seiferman-Nelson, RN, Bonny Granfield, RN, BScN

Blood (2014) 124 (21): 5050.

https://doi.org/10.1182/blood.V124.21.5050.5050

Published: 2014

Journal Articles

Immune Tolerance Induction in Severe Hemophilia a Patients Using Wilate®, a Von Willebrand Factor/Factor VIII Concentrate

John K. Wu, MBBS, MSc, FRCPC, Celina Woo, RN, MN, Erica Crilly, RN, MN

Blood (2014) 124 (21): 5057.

https://doi.org/10.1182/blood.V124.21.5057.5057

Published: 2014

Journal Articles

Surgery in Von Willebrand Disease (VWD) Is Facilitated By a Novel 1:1 Plasma Derived Human Factor VWF/VIII Concentrate

Alok Srivastava, MD, Margit Serban, Prof. Dr., Sylvia Werner, Bruce A. Schwartz, PhD, Sigurd Knaub, PhD, Craig M. Kessler, MD

Blood (2014) 124 (21): 1504.

https://doi.org/10.1182/blood.V124.21.1504.1504

Published: 2014

Journal Articles

Myeloid-Derived Suppressor Cell (MDSC) Dynamics In FVIII-Exposed Hemophilia A Mice: Novel Therapeutic Implications

Brooke Snetsinger, MSc, Caroline Lin, BSc, Willy Weng, BSc, Alyssa Cull, MSc, Kate Sponagle, Christine Hough, PhD, David Lillicrap, Michael J. Rauh, MD, PhD

Blood (2013) 122 (21): 3569.

https://doi.org/10.1182/blood.V122.21.3569.3569

Published: 2013

Journal Articles

ADAMTS13 Content of Plasma-Derived Factor VIII-Von Willebrand Factor Concentrates

Flora Peyvandi, Pier Mannuccio Mannucci, MD, Carla Valsecchi, Silvia Pontiggia, Jonathan Bernstein, MS, MD, Stefano Guazzini, PhD, Anastassios Retzios, PhD

Blood (2012) 120 (21): 3383.

https://doi.org/10.1182/blood.V120.21.3383.3383

Published: 2012

Journal Articles

Pharmacokinetic Evaluation of a Newly Introduced Von Willebrand Factor Concentrate At Two London Haemophilia Centres

Oliver Hegener, PhD, Natasha M Wiles, BSc, MBBS, MRCP, MRCPath, Anne Wareing, Bella Madan, MD, MRCP, FRCPath, Steve K Austin, Dr

Blood (2012) 120 (21): 3384.

https://doi.org/10.1182/blood.V120.21.3384.3384

Published: 2012

Journal Articles

Descriptive Evaluation of Age-Related Differences in Clinical Manifestation and Treatment of Von Willebrand's Disease in an Open-Label, Prospective, Non-Interventional Study (wilate ® -SET)

Oliver Hegener, PhD, Inge Scharrer, MD, PhD, Jennifer Feddern, Wolfgang A. Miesbach V, MD, PhD, Mario Von Depka, Janos Kadar

Blood (2012) 120 (21): 4630.

https://doi.org/10.1182/blood.V120.21.4630.4630

Published: 2012

Journal Articles

A Neonate with Type 3 Von Willebrands Disease and Life Threatening Bleeding Treated Successfully with a FVIII/VWF Concentrate (wilate®)

Oliver Hegener, PhD, Jemma Efford, Jack L Bartram, Lesley Henderson, Kate Khair

Blood (2012) 120 (21): 4633.

https://doi.org/10.1182/blood.V120.21.4633.4633

Published: 2012

Journal Articles

Results of a Prospective, Open-Label Trial to Assess the Efficacy, Safety and Immunogenicity of Wilate ® in Children Under 6 Years of Age with Inherited Von Willebrand Disease,

Ulrike Nowak-Gottl, MD, Alexandra Russo, MD, Anne Kruempel, MD, Martina Jansen, Sigurd Knaub, PhD

Blood (2011) 118 (21): 3330.

https://doi.org/10.1182/blood.V118.21.3330.3330

Published: 2011

Journal Articles

Pseudoallergy Induced by Factor VIII Injection in Three Subjects with Hemophilia A

Caroline Pfeiffer, Géraldine Lavigne-Lissalde, Georges-Etienne Rivard, MD

Blood (2011) 118 (21): 4353.

https://doi.org/10.1182/blood.V118.21.4353.4353

Published: 2011

Journal Articles

Assessing Haemostatic Efficacy In VWF/FVIII Replacement Therapy Trials Utilizing Subjective Vs. Objective Criteria – a Way to Improve Comparability and Accuracy of Clinical Outcome.

Craig M. Kessler, MD, Bruce A. Schwartz, PhD, Oliver Hegener, Olaf Walter, MD, Sigurd Knaub, PhD

Blood (2010) 116 (21): 1424.

https://doi.org/10.1182/blood.V116.21.1424.1424

Published: 2010

NARROW

Clinical Study to Investigate the Efficacy and Safety of Wilate during Prophylaxis in Previously Treated Patients with Von Willebrand Disease (VWD)

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

A Novel Approach to Immune Tolerance Induction in Hemophilia Α with Factor VIII Inhibitor

Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project

Final Results from a Non-Interventional Safety and Efficacy Study of a VWF/FVIII Concentrate (wilate ® ) in Patients with Von Willebrand Disease

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

Immune Tolerance Induction in Hemophilia A Patients Using Wilate® —a Canadian 10 Year Study (PREVAIL)

Management of Perioperative Anticoagulation in Patients with VWD

A Case Series Evaluating the Use of a Von Willebrand Factor/Factor VIII Concentrate (Wilate®) for Immune Tolerance Induction (ITI) in Children with Severe Factor VIII Deficiency

Immune Tolerance Induction in Severe Hemophilia a Patients Using Wilate®, a Von Willebrand Factor/Factor VIII Concentrate

Surgery in Von Willebrand Disease (VWD) Is Facilitated By a Novel 1:1 Plasma Derived Human Factor VWF/VIII Concentrate

Myeloid-Derived Suppressor Cell (MDSC) Dynamics In FVIII-Exposed Hemophilia A Mice: Novel Therapeutic Implications

ADAMTS13 Content of Plasma-Derived Factor VIII-Von Willebrand Factor Concentrates

Pharmacokinetic Evaluation of a Newly Introduced Von Willebrand Factor Concentrate At Two London Haemophilia Centres

Descriptive Evaluation of Age-Related Differences in Clinical Manifestation and Treatment of Von Willebrand's Disease in an Open-Label, Prospective, Non-Interventional Study (wilate ® -SET)

A Neonate with Type 3 Von Willebrands Disease and Life Threatening Bleeding Treated Successfully with a FVIII/VWF Concentrate (wilate®)

Results of a Prospective, Open-Label Trial to Assess the Efficacy, Safety and Immunogenicity of Wilate ® in Children Under 6 Years of Age with Inherited Von Willebrand Disease,

Pseudoallergy Induced by Factor VIII Injection in Three Subjects with Hemophilia A

Assessing Haemostatic Efficacy In VWF/FVIII Replacement Therapy Trials Utilizing Subjective Vs. Objective Criteria – a Way to Improve Comparability and Accuracy of Clinical Outcome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only